Lenvatinib Mesylate (CAS 857890-39-2)

Application and positioning

Lenvatinib mesylate is a multi-targeted kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFR-alpha, KIT and RET, supplied as the mesylate salt. It is used in oral capsules for differentiated thyroid cancer, hepatocellular carcinoma and advanced renal cell carcinoma. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Neratinib Maleate (CAS 915942-22-2)
• Nintedanib Ethanesulfonate (CAS 656247-18-6)
• Niraparib (CAS 1038915-60-4)
• Niraparib Tosylate Monohydrate (CAS 1613220-15-7)
• N-(2-Chloro-4-hydroxyphenyl)-N’-cyclopropyl-urea (CAS 796848-79-8)
• 4-Chloro-7-methoxyquinoline-6-carboxamide (CAS 417721-36-9)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.